17-7674859-C-T
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_000546.6(TP53):c.672G>A(p.Glu224Glu) variant causes a splice region, synonymous change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000546.6 splice_region, synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 34
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Li-Fraumeni syndrome 1 Pathogenic:2
- -
This variant is considered likely pathogenic. mRNA analysis has demonstrated abnormal mRNA splicing occurs [PMID: 28475293]. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 28475293, 30709381]. -
Hereditary cancer-predisposing syndrome Pathogenic:2
The c.672G>A pathogenic mutation (also known as p.E224E), located in coding exon 5 of the TP53 gene, results from a G to A substitution at nucleotide position 672. This mutation has been identified in several patients meeting Chompret criteria (Gallardo-Alvarado LN et al. BMC Cancer, 2019 Feb;19:118; Ambry internal data). This mutation was also reported as occurring de novo in a 17 year old individual diagnosed with two sarcomas (Austin F et al. Pediatr Blood Cancer, 2017 Nov;64:). This nucleotide substitution does not change the at codon 224. However, this change occurs in the last base pair of coding exon 5, which makes it likely to have some effect on normal mRNA splicing. This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site and may result in the creation or strengthening of a novel splice donor site. An in vivo splicing assay has shown that this alteration results in aberrant splicing which activates a cryptic splice site, resulting in a frameshifted mRNA (Supek F et al. Cell, 2014 Mar;156:1324-1335). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
- -
Li-Fraumeni syndrome Pathogenic:1
This sequence change affects codon 224 of the TP53 mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the TP53 protein. RNA analysis indicates that this variant induces altered splicing and may result in an absent or altered protein product. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with Li-Fraumeni syndrome associated tumors (PMID: 28475293). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 80709). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in activation of a cryptic splice site, and produces a non-functional protein and/or introduces a premature termination codon (PMID: 24630730, 28475293; internal data). For these reasons, this variant has been classified as Pathogenic. -
not provided Other:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at